How can you benefit from new market opportunities in OTC after the shock of covid-19?

COVID-19, OTC

All of our countries implemented sanitary measures for stopping the global Covid-19 pandemic:...

AplusA 30+ years Anniversary - Interview #1

AplusA News

In ‘21, we are celebrating our 30+.

AplusA is actually 30+ years old this year... But what does...

AplusA Anniversaire 30+ ans - Interview #1

AplusA News

C’est l’année 21, mais nous en célébrons plus de 30.

En 2021, AplusA fête - non pas ses 30 -...

Our brand new 2020 Syndicated Surveys

COVID-19, Syndicated Studies

Our range of syndicated studies now covers over 30 indications, many of them with results...

COVID-19 2nd Phase - Impact on Physicians’ Practice - Syndicated Study

hemato-oncology, COVID-19, Syndicated Studies, Oncology

How does COVID-19 affect the HCPS relationships with patients and with the pharmaceutical...

mRCC: promising new combinations lead to disruption in L1 and L2

Syndicated Studies, Oncology

Targeted therapies, particularly tyrosine kinase inhibitors (TKI) dominate the treatment of...

COVID-19 road to recovery: 5 key insights from our syndicated study

COVID-19, Syndicated Studies

As the global number of infected cases surpasses 46 million (Nov 2, 2020), there is a non-stop...

Social Media Insights: ASCO 2020 Part 2

Social Media Listening

The American Society of Oncologists (ASCO) annual meeting is a major fixture in the global...

Welcoming the new-look AplusA website!

AplusA News, Digital

You might have noticed that our site looks a little different. We wanted to share the story...

DLBCL Patient Insights in the US and EU5

hemato-oncology, DLBCL market

When working on a new or existing brand within the DLBCL market it's important to have up to...